Lempinen M, Stenman U H, Puolakkainen P, Hietaranta A, Haapiainen R, Kemppainen E
Second Dept. of Surgery, Helsinki University Central Hospital, Helsinki, Finland.
Scand J Gastroenterol. 2003 Jun;38(6):666-75. doi: 10.1080/00365520310000357.
Trypsinogen activation within acinar cells plays a crucial role in the pathogenesis of acute pancreatitis (AP). Our aim was to characterize temporal changes of trypsinogen-1, trypsinogen-2, complexes of trypsin-1-alpha1-antitrypsin (T1-AAT) and trypsin-2-alpha1-antitrypsin (T2-AAT), trypsinogen activation peptide (TAP) and pancreatic secretory trypsin inhibitor (PSTI) in patients with AP.
The study comprised 64 consecutive patients with AP (19 with severe disease) and 32 controls. The concentrations of trypsinogen-1 and -2, PSTI, T1-AAT and T2-AAT were determined by time-resolved immunofluorometric assays (IFMA), and TAP was measured using a competitive enzyme immunoassay from serum and urine.
The concentrations of trypsinogen-1 and -2 in serum reflected similar patterns, but excretion of trypsinogen-1 into urine was markedly lower than that of trypsinogen-2, the concentration of which correlated strongly with disease severity. The concentrations of T1-AAT were no higher in severe AP than in mild AP, while T2-AAT concentrations were significantly higher in severe than in mild disease. PSTI increased over the course of several days, showing strong correlation with disease severity. The concentrations of plasma and urinary TAP decreased rapidly to undetectable levels. During the early phase of AP, TAP correlated with the disease severity in plasma and urine but there was no difference between controls and patients with mild AP.
More pronounced changes in trypsinogen-2 and its complex with AAT than in those of trypsinogen-1 were demonstrated, suggesting that trypsinogen-2 might play a more important role in the pathogenesis of AP than earlier believed. Urinary PSTI showed features warranting further investigations as a marker of disease severity.
腺泡细胞内胰蛋白酶原激活在急性胰腺炎(AP)发病机制中起关键作用。我们的目的是描述AP患者中胰蛋白酶原-1、胰蛋白酶原-2、胰蛋白酶-1-α1抗胰蛋白酶(T1-AAT)和胰蛋白酶-2-α1抗胰蛋白酶(T2-AAT)复合物、胰蛋白酶原激活肽(TAP)及胰腺分泌性胰蛋白酶抑制剂(PSTI)的时间变化。
该研究纳入64例连续的AP患者(19例为重症)和32例对照。采用时间分辨免疫荧光分析法(IFMA)测定胰蛋白酶原-1和-2、PSTI、T1-AAT和T2-AAT的浓度,并用竞争性酶免疫分析法测定血清和尿液中的TAP。
血清中胰蛋白酶原-1和-2的浓度反映出相似模式,但胰蛋白酶原-1的尿排泄量明显低于胰蛋白酶原-2,后者的浓度与疾病严重程度密切相关。重症AP患者的T1-AAT浓度并不高于轻症AP患者,而重症疾病患者的T2-AAT浓度明显高于轻症患者。PSTI在数天内升高,与疾病严重程度密切相关。血浆和尿液中TAP的浓度迅速降至无法检测的水平。在AP早期,血浆和尿液中的TAP与疾病严重程度相关,但对照组与轻症AP患者之间无差异。
与胰蛋白酶原-1相比,胰蛋白酶原-2及其与AAT的复合物变化更为明显,提示胰蛋白酶原-2在AP发病机制中可能比之前认为的发挥更重要的作用。尿PSTI作为疾病严重程度标志物的特征值得进一步研究。